Skip to main content

Advertisement

Table 5 Joint model estimation on population (N = 2708, 632 recurrent events, 212 deaths)

From: Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort

Variables (% of women) Recurrent event Overall death
HR 95% CI HR 95% CI
Estrogen/Progesterone receptor status
 +/− vs +/+ (18.6%) 1.40 1.10, 1.79 2.51 1.20, 5.30
 −/+ vs +/+ (4.1%) 1.00 0.62, 1.59 5.63 1.55, 20.46
 −/− vs +/+ (15.6%) 2.14 1.70, 2.70 9.76 4.39, 21.75
Grade
 moderately differentiated vs well differentiated (36.4%) 1.61 1.15, 2.27 3.12 0.99, 9.91
 poorly differentiated vs well differentiated (48.5%) 1.90 1.36, 2.66 6.54 2.02, 21.18
Tumor size (≥ 2 cm vs < 2 cm) (20.5%) 1.64 1.33, 2.01 4.70 2.27, 9.75
Axillary nodal involvement (yes vs no) (30.0%) 1.54 1.26, 1.86 5.23 2.63, 10.42
Recent MHT use before diagnosis (yes vs no) (44.3%) 0.75 0.62, 0.92   
Smoking status first follow-up after diagnosis
 ex-smoker vs never smoker (36.9%) 1.20 1.00, 1.44   
 current smoker vs never smoker (6.5%) 1.55 1.16, 2.07   
Year of diagnosis
 1995–1999 vs 1990–1994 (28.9%) 0.90 0.72, 1.13   
 2000–2003 vs 1990–1994 (32.3%) 0.72 0.56,0.94   
 2004–2008 vs 1990–1994 (27.4%) 0.61 0.43, 0.89   
Age at breast cancer diagnosis (year)
 [50–60) vs < 50 (44.1%)    1.80 0.68, 4.79
 [60–70) vs < 50 (38.0%)    4.50 1.29, 15.78
  ≥ 70 vs < 50 (9.5%)    9.08 1.89,43.69
Menopausal status at breast cancer diagnosis
 postmenopausal woman - no use of MHT vs premenopausal woman (27.1%)    1.39 0.58, 3.32
 postmenopausal woman-less than 5 years of cumulated MHT use vs premenopausal woman (29.3%)    0.79 0.32, 1.97
 postmenopausal woman-more than 5 years of cumulated MHT use vs premenopausal woman (28.8%)    0.35 0.11, 1.10
θ 1.01 (σ = 0.05) p-value< 0.001
α 4.29 (σ = 0.77) p-value< 0.001
  1. HR hazard ratio, σ standard error, 95% CI 95% Confidence Interval, MHT menopausal hormonal treatment